EGFR and lung cancer: Irrespective of the timing of the occurrence of mutations, analysis of EGFR mutations has been a crucial step for the application of tyrosine-kinase-inhibitor (TKI)-based targeted therapy in patients with lung cancer harboring EGFR mutations [10].